查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403512

到 2030 年肌瘤摘除的市场预测：按产品类型、最终用户和地区进行的全球分析

Myomectomy Market Forecasts to 2030 - Global Analysis By Product, Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球肌瘤摘除市场规模为 7.5659 亿美元，预计到 2030 年将达到 15.8073 亿美元，预测期内复合年增长率为 11.1%。

肌瘤摘除是一种外科手术，旨在从子宫肌肉壁上移除称为子宫肌瘤的非癌性生长物。对于想要避免子宫切除术或想要保留生育能力的女性来说，这是一个可行的选择。此外，这种手术可以使用多种技术进行，包括开放性手术、腹腔镜手术和机器人辅助手术。

根据妇女健康研究协会的报告，美国约有2600万15岁至50岁的女性患有子宫肌瘤。

子宫肌瘤盛行率增加

子宫肌瘤是常见的良性肿瘤，影响大量女性，尤其是在生育期。例如，根据伊利诺伊州公共卫生部的数据，大约 77% 的生产妇女可能患有子宫肌瘤。因此，随着越来越多的女性被诊断出患有子宫肌瘤，越来越需要有效的治疗解决方案来控制由此产生的症状。此外，腹腔镜和机器人辅助手术等微创技术在子宫肌瘤切除术中也越来越受欢迎。子宫肌瘤盛行率的增加刺激了对子宫肌瘤摘除的需求并推动市场扩张。

生育问题

儘管肌瘤摘除的目的是透过切除子宫肌瘤来保护生育能力，但它也会影响生育能力。手术，尤其是子宫肌瘤是多个或较大的，可能会导致子宫疤痕或变化，进而影响生育能力。肌瘤摘除对生育问题的担忧影响了未来想要孩子的女性。这可能会影响治疗决策流程，甚至限制市场扩张。

微创手术需求不断成长

越来越多的患者喜欢腹腔镜或机器人辅助肌瘤摘除切除术等微创手术，以获得更快的恢復时间、更少的疤痕并更快地恢復日常活动。这种日益增长的偏好与对有效且微创治疗方法的渴望不谋而合，特别是在寻求保留生育能力的女性身上。此外，提供这些先进手术的医疗保健提供者将能够吸引更多寻求肌瘤摘除的患者，满足对微创选择不断增长的需求并扩大他们的市场。

手术以外的选择

子宫动脉栓塞（UAE）和聚焦超音波手术（FUS）等先进的非手术治疗为无需手术的子宫肌瘤治疗提供了有效的选择。这些非手术治疗的可用性和成功率不断提高，对传统肌瘤摘除市场构成了挑战，有可能减少对外科手术的需求，并增加无需手术干预的子宫肌瘤切除术的可用性。 。

COVID-19 的影响

COVID-19 疫情严重影响了女性医疗保健和子宫肌瘤摘除市场。 COVID-19 的爆发导致诊断和治疗的延误以及医疗机构中非紧急治疗的延迟。此外，供应链中断导致难以取得子宫肌瘤摘除所需的医疗用品。此外，医院挪用了用于 COVID-19 治疗的资金，影响了他们对非紧急医疗活动的关注。因此，COVID-19 限制了子宫肌瘤摘除市场的成长。

在预测期内，腹腔镜子宫肌瘤摘除部门预计将是最大的。

腹腔镜子宫肌瘤摘除预计占最大份额。腹腔镜肌瘤摘除是一种微创手术，用于切除子宫肌瘤。此手术使用一个小切口，透过该切口插入特殊器械和腹腔镜，以提供子宫的放大视图。其他好处包括更短的住院时间、更快的康復和更少的术后併发症。越来越多的患者对微创选择的偏好以及腹腔镜技术的进步继续使该领域成为子宫肌瘤的治疗方法。

医院和诊所领域预计在预测期内复合年增长率最高

预计医院和诊所部门在预测期内将出现良好的成长。医院和诊所配备先进的医疗基础设施和熟练的医疗专业人员，为寻求各种子宫肌瘤治疗方法的患者提供服务。我们提供全面的诊断评估、手术专业知识和术后护理，以满足患者对各种手术方法的需求，包括腹腔镜手术、机器人辅助手术和开放式肌瘤摘除。此外，医院和诊所在提供专业护理方面发挥着至关重要的作用，透过肌瘤摘除为子宫肌瘤的可及性和综合管理做出了重大贡献。

比最大的地区

由于患有子宫疾病的女性人数不断增加以及新兴经济体主要企业对手术器械行业的投资增加，亚太地区在估计期间占据了最大的市场占有率。中国和日本在扩大肌瘤摘除市场方面发挥重要作用。包括外科医生和妇科医生在内的高技能医疗人员的供应不断增加，以及对用于研究目的的基因晶片等技术先进的医疗技术的需求不断增加，是这一增长的主要原因。

复合年增长率最高的地区：

由于子宫肌瘤盛行率的上升和子宫肌瘤摘除的技术进步，预计北美在预测期内将出现有益的增长。根据美国妇女健康局2021年2月更新的资料，预计约20%至80%的女性会在50岁时罹患子宫肌瘤。 40多岁到50岁出头的女性最容易罹患子宫肌瘤。儘管并非所有子宫肌瘤都会引起症状，但患有子宫肌瘤的人通常会发现与子宫肌瘤一起生活很困难。如上所述，由于美国子宫肌瘤的高负担，市场预计将成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肌瘤摘除市场：副产品

  • 腹腔镜动力粉碎器
  • 腹腔镜封堵器
  • 和谐女性
  • 其他产品

第六章全球肌瘤摘除市场：依类型

  • 腹部子宫切除术
  • 腹腔镜切除术
  • 子宫镜切除术术
  • 机器人切除术

第七章全球肌瘤摘除市场：依最终用户分类

  • 门诊手术中心
  • 医院/诊所
  • 其他最终用户

第八章全球肌瘤摘除市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Medtronic
  • Conmed Corporation
  • Stryker Corporation
  • Insightec
  • Hologic, Inc
  • Cooper Surgical Inc
  • Intuitive Surgical
  • Braun Melsungen AG
  • Minerva Surgical Inc
  • Johnson And Johnson Services Inc.
  • Karl Storz
  • Boston Scientific Corporation
  • General Electric Company
  • F. Hoffmann-La Roche Ltd
  • Richard Wolf Medical Instruments
  • Siemens
  • Bayer
  • AbbVie Inc.
  • Halt Medical, Inc.
Product Code: SMRC24737

According to Stratistics MRC, the Global Myomectomy Market is accounted for $756.59 million in 2023 and is expected to reach $1580.73 million by 2030 growing at a CAGR of 11.1% during the forecast period. A myomectomy is a surgical procedure aimed at removing noncancerous growths known as uterine fibroids from the muscular wall of the uterus. It is a viable alternative for women who want to avoid a hysterectomy or maintain their fertility. Furthermore, a number of techniques, such as open surgery, laparoscopy, and robotic-assisted surgery, can be used to carry out this procedure.

According to the Society for Women's Health Research report, in the U.S. approximately 26 million women ages 15-50 have uterine fibroids.

Market Dynamics:

Driver:

Growing prevalence of uterine fibroids

Uterine fibroids are common benign tumours affecting a substantial number of women, particularly during their reproductive years. For instance, according to the Illinois Department of Public Health, around 77% of women of childbearing age may have uterine fibroids. Therefore, as more women have uterine fibroids diagnoses, there is a growing need for efficient treatment solutions to manage the resulting symptoms. Furthermore, minimally invasive techniques such as laparoscopy and robotic-assisted surgery are gaining popularity in myomectomy. This growing prevalence of uterine fibroids fuels the demand for myomectomy procedures, propelling the market's expansion

Restraint:

Fertility concerns

Myomectomy has the potential to affect fertility ability, even if the aim is to protect fertility by removing uterine fibroids. The surgical procedure, especially if multiple or large fibroids are removed, might lead to scarring or alterations in the uterus, potentially affecting reproductive capabilities. Women who wish to have children in the future are influenced by their concern about possible issues with their fertility after a myomectomy. This affects their decision-making process regarding treatment and may even restrict the market's expansion.

Opportunity:

Rising demand for minimally invasive procedures

Patients increasingly favour minimally invasive techniques like laparoscopic or robotic-assisted myomectomy due to reduced recovery times, less scarring, and a quicker return to daily activities. This growing preference aligns with the desire for effective yet less invasive treatments, especially among women seeking fertility preservation. Furthermore, healthcare providers offering these advanced procedures can attract more patients seeking myomectomy, addressing the rising demand for minimally invasive options and potentially expanding the market.

Threat:

Non-surgical alternatives

Advanced non-surgical treatments like uterine artery embolisation (UAE) or focused ultrasound surgery (FUS) offer effective options for treating uterine fibroids without surgery. The availability and increasing success rates of these non-surgical treatments pose a challenge to the traditional myomectomy market, potentially reducing the demand for surgical procedures and impacting the market's growth by offering compelling alternatives for fibroid management without surgical interventions.

COVID-19 Impact

The COVID-19 epidemic severely impacted women's healthcare and the market for myomectomy procedures. It caused delays in diagnosis and treatment, as well as the postponement of non-urgent treatments in the medical field. Also, interruptions in the supply chain impacted the accessibility of medical supplies required for myomectomy operations. In addition, hospitals diverted funds for COVID-19 therapy, which affected the focus on non-urgent medical operations. Consequently, COVID-19 limited the growth of the myomectomy market.

The laparoscopic myomectomy segment is expected to be the largest during the forecast period

The laparoscopic myomectomy segment is estimated to hold the largest share. Laparoscopic myomectomy involves a minimally invasive surgical procedure to remove uterine fibroids. This technique utilizes small incisions through which specialized instruments and a laparoscope are inserted, providing a magnified view of the uterus. Moreover, it offers benefits like shorter hospital stays, faster recuperation, and reduced postoperative complications. With increasing patient preference for minimally invasive options and advancements in laparoscopic techniques, this segment continues to gain traction as a preferred method for treating uterine fibroids.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

The hospitals & clinics segment is anticipated to have lucrative growth during the forecast period. Hospitals and clinics equipped with advanced medical infrastructure and skilled healthcare professionals cater to patients seeking various treatment options for uterine fibroids. They offer comprehensive diagnostic evaluations, surgical expertise, and postoperative care, addressing patient needs with diverse surgical approaches such as laparoscopic, robotic-assisted, or open myomectomy procedures. In addition, hospitals and clinics play a pivotal role in delivering specialised care, contributing significantly to the accessible and comprehensive management of uterine fibroids through myomectomy.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to the increasing number of women suffering from uterine disorders and the rising investment in the surgical device industry by key players in developing economies. China and Japan have played a significant role in the market expansion for myomectomy procedures. The supply of highly skilled medical personnel, including surgeons and gynaecologists, as well as the rising need for technologically sophisticated medical technologies, such as gene chips, for research purposes, are the main reasons for this growth.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to the rising prevalence of uterine fibroid and technological advancements in myomectomy procedures. According to the data updated by the United States Office on Women's Health in February 2021, it was estimated that about 20 percent to 80 percent of women developed fibroids by the time they reached age 50. Women in their 40s and early 50s are most likely to develop uterine fibroids. While not all fibroids cause symptoms, those who do frequently find living with their fibroids to be difficult. Thus, the high burden of uterine fibroids in the United States is expected to boost market growth.

Key players in the market:

Some of the key players in the Myomectomy Market include Medtronic, Conmed Corporation, Stryker Corporation, Insightec, Hologic, Inc, Cooper Surgical Inc, Intuitive Surgical, Braun Melsungen AG, Minerva Surgical Inc, Johnson And Johnson Services Inc., Karl Storz, Boston Scientific Corporation, General Electric Company, F. Hoffmann-La Roche Ltd, Richard Wolf Medical Instruments, Siemens, Bayer, AbbVie Inc. and Halt Medical, Inc.

Key Developments:

In November 2022, Olympus announced the market launch of the moresolution Power Morcellator, manufactured by TROKAMED GmbH and available in the United States through a distribution agreement with Olympus America, Inc. The moresolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens. Olympus's pneumoLiner and the moresolution Morcellator can provide select patients with a laparoscopic surgical option.

In April 2022, Ethicon, part of Johnson & Johnson MedTech, launched the ENSEAL X1 Straight Jaw Tissue Sealer. The ENSEAL X1 Straight Jaw is indicated for use in open and laparoscopic general, gynecological, and urologic procedures.

Products Covered:

  • Laparoscopic Power Morcellators
  • Laparoscopic Sealer
  • Harmonic Scalpel
  • Other Products

Types Covered:

  • Abdominal Myomectomy
  • Laparoscopic Myomectomy
  • Hysteroscopic Myomectomy
  • Robotic Myomectomy

End Users Covered:

  • Ambulatory Surgical Centers
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Myomectomy Market, By Product

  • 5.1 Introduction
  • 5.2 Laparoscopic Power Morcellators
  • 5.3 Laparoscopic Sealer
  • 5.4 Harmonic Scalpel
  • 5.5 Other Products

6 Global Myomectomy Market, By Type

  • 6.1 Introduction
  • 6.2 Abdominal Myomectomy
  • 6.3 Laparoscopic Myomectomy
  • 6.4 Hysteroscopic Myomectomy
  • 6.5 Robotic Myomectomy

7 Global Myomectomy Market, By End User

  • 7.1 Introduction
  • 7.2 Ambulatory Surgical Centers
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Myomectomy Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Medtronic
  • 10.2 Conmed Corporation
  • 10.3 Stryker Corporation
  • 10.4 Insightec
  • 10.5 Hologic, Inc
  • 10.6 Cooper Surgical Inc
  • 10.7 Intuitive Surgical
  • 10.8 Braun Melsungen AG
  • 10.9 Minerva Surgical Inc
  • 10.10 Johnson And Johnson Services Inc.
  • 10.11 Karl Storz
  • 10.12 Boston Scientific Corporation
  • 10.13 General Electric Company
  • 10.14 F. Hoffmann-La Roche Ltd
  • 10.15 Richard Wolf Medical Instruments
  • 10.16 Siemens
  • 10.17 Bayer
  • 10.18 AbbVie Inc.
  • 10.19 Halt Medical, Inc.

List of Tables

  • Table 1 Global Myomectomy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 4 Global Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 5 Global Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 6 Global Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 8 Global Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 9 Global Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 10 Global Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 11 Global Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 12 Global Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 13 Global Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 14 Global Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 15 Global Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 16 North America Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 17 North America Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 18 North America Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 19 North America Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 20 North America Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 21 North America Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 22 North America Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 23 North America Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 24 North America Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 25 North America Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 26 North America Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 27 North America Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 28 North America Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 29 North America Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 30 North America Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 31 Europe Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 32 Europe Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 33 Europe Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 34 Europe Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 35 Europe Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 36 Europe Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 37 Europe Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 38 Europe Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 39 Europe Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 40 Europe Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 41 Europe Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 42 Europe Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 43 Europe Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 44 Europe Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 45 Europe Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 46 Asia Pacific Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 47 Asia Pacific Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 48 Asia Pacific Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 49 Asia Pacific Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 50 Asia Pacific Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 51 Asia Pacific Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 52 Asia Pacific Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 53 Asia Pacific Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 54 Asia Pacific Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 55 Asia Pacific Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 56 Asia Pacific Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 57 Asia Pacific Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 58 Asia Pacific Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 59 Asia Pacific Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 60 Asia Pacific Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 61 South America Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 South America Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 63 South America Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 64 South America Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 65 South America Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 66 South America Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 67 South America Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 68 South America Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 69 South America Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 70 South America Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 71 South America Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 72 South America Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 South America Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 74 South America Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 75 South America Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Middle East & Africa Myomectomy Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Middle East & Africa Myomectomy Market Outlook, By Product (2021-2030) ($MN)
  • Table 78 Middle East & Africa Myomectomy Market Outlook, By Laparoscopic Power Morcellators (2021-2030) ($MN)
  • Table 79 Middle East & Africa Myomectomy Market Outlook, By Laparoscopic Sealer (2021-2030) ($MN)
  • Table 80 Middle East & Africa Myomectomy Market Outlook, By Harmonic Scalpel (2021-2030) ($MN)
  • Table 81 Middle East & Africa Myomectomy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 82 Middle East & Africa Myomectomy Market Outlook, By Type (2021-2030) ($MN)
  • Table 83 Middle East & Africa Myomectomy Market Outlook, By Abdominal Myomectomy (2021-2030) ($MN)
  • Table 84 Middle East & Africa Myomectomy Market Outlook, By Laparoscopic Myomectomy (2021-2030) ($MN)
  • Table 85 Middle East & Africa Myomectomy Market Outlook, By Hysteroscopic Myomectomy (2021-2030) ($MN)
  • Table 86 Middle East & Africa Myomectomy Market Outlook, By Robotic Myomectomy (2021-2030) ($MN)
  • Table 87 Middle East & Africa Myomectomy Market Outlook, By End User (2021-2030) ($MN)
  • Table 88 Middle East & Africa Myomectomy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 89 Middle East & Africa Myomectomy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 90 Middle East & Africa Myomectomy Market Outlook, By Other End Users (2021-2030) ($MN)